Epigen to license LPA1 receptor small molecule program to Novo Nordisk
The company received series A funding under the round led by Oxford Sciences Innovation (OSI), and the participants include Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia and personal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.